Sharpkil

Cefuroxime

Description

Cefuroxime is one of the bactericidal second generation cephalosporin antibiotic which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many beta-lactamase producing strains. It is indicated for the treatment of infections caused by sensitive bacteria.

Sharpkil 250: Each film coated tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 250 mg. Sharpkil 500: Each film coated tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 500 mg. Sharpkil 70: Each 5 ml suspension contains Cefuroxime Axetil BP equivalent to Cefuroxime 125 mg.
Pharyngitis/tonsillitis caused by Streptococcus pyogenes Acute bacterial otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta lactamase-producing strains), Moraxella Catarrhalis (including beta-lactamase-producing strains) or Streptococcus pyogenes. Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae, or Haemophilus influenzae (nonbeta-lactamase-producing strains only) Lower respiratory tract infections including pneumoniae, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, Escherichia coli. Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by Streptococcus penumoniae, Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). Skin and Skin-Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, Escherichia coli, Klebsiella spp., and Enterobacter spp. Urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neiseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Early Lyme disease (erythema migrans) caused by Borrelia burgdorferi. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseira menintitidis, and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Surgical Prophylaxis: Prophylaxis against infections in abdominal, pelvic, orthopedic, cardiac, pulmonary, esophageal and vascular surgery where there is increased risk for infection.
Oral : INFECTIONS DOSAGE DURATION Tablet (May be administered without regard to meals) Adolescents & adults(13 years & above) Pharyngitis or Tonsillitis 250 mg twice daily 5-10 days Acute bacterial maxillary sinusitis 250 mg twice daily 10 days Acute bacterial exacerbation of chronic bronchitis 250-500 mg twice daily 10 days Secondary bacterial infections of acute bronchitis 250-500 mg twice daily 5-10 days Uncomplicated skin & skin-structure infections 250-500 mg twice daily 10 days Uncomplicated urinary tract infection 125-250 mg twice daily 7-10 days Uncomplicated gonorrhea 1000 mg single dose - - - Lyme disease 500 mg twice daily 20 days Paediatric patients (Upto12 years) (Who can swallow tablets whole) Pharyngitis or Tonsillitis 125 mg twice daily 5-10 days Acute otitis media 250 mg twice daily 10 days Acute bacterial maxillary sinusitis 250 mg twice daily 10 days Suspension (Must be administered with food. Shake the bottle well before each use) Paediatric patients (3 months to 12 years) Pharyngitis or Tonsillitis 20 mg/kg/day in two divided doses 5-10 days Acute otitis media 30 mg/kg/day in two divided doses 10 days Acute bacterial maxillary sinusitis 30 mg/kg/day in two divided doses 10 days
Patients with known allergy to cephalosporins & pseudomembranous colitis are contraindicated.
Cefuroxime should be given with care to patients receiving concurrent treatment with potent diuretics & who have history of colitis.
Generally Cefuroxime is well tolerated. However, a few side effects like nausea, vomiting, diarrhoea, abdominal discomfort or pain may occur. As with other broad-spectrum antibiotics, prolonged administration of Cefuroxime may result in overgrowth of nonsusceptible microorganisms. Rarely (<0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear.
Concomitant administration of probenecid with Cefuroxime increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of postprandial absorption.
Pregnancy: While all antibiotics should be avoided in the first trimester if possible. However, Cefuroxime has been safely used in later pregnancy to treat urinary and other infections. Nursing mothers: Cefuroxime is excreted into the breast milk in small quantities. However, the possibility of sensitizing the infant should be kept in mind.
Signs and symptoms: Overdosage of Cefuroxime can cause cerebral irritation leading to convulsions. Management: Serum levels of Cefuroxime can be reduced by haemodialysis and peritoneal dialysis.
Sharpkil 250: Each box contains 2 Alu-Alu blister strips of 6 tablets. Sharpkil 500: Each box contains 1 Alu-Alu blister strips of 6 tablets. Sharpkil 70: Each bottle contains dry powder for 70 ml suspension.